Abstract
Mark Huffman asks what happened to the polypill to reduce cardiovascular risk, explores the promise it still holds, and considers how best to turn promise into reality.
MeSH terms
-
Cardiovascular Agents / administration & dosage*
-
Cardiovascular Diseases / prevention & control*
-
Clinical Trials as Topic
-
Humans
-
Medication Adherence
-
Primary Prevention
-
Secondary Prevention / methods*
-
United States
-
United States Food and Drug Administration
Grants and funding
No funding was received for this work.